Evidence map›Paper›PMID 40362545›Full record

ReviewInternational journal of molecular sciences2025

The Possibility of Plasma Membrane Transporters as Drug Targets in Oral Cancers.

Chiharu Sogawa, Katsumitsu Shimada, Keisuke Nakano

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chiharu SogawaDepartment of Food and Health Sciences, Faculty of Environmental Studies, Hiroshima Institute of Technology, 2-1-1 Miyake, Saeki-ku, Hiroshima 731-5193, Japan.ORCID 0000-0002-5606-0710
Katsumitsu ShimadaDepartment of Clinical Phathophysiology, Matsumoto Dental University, 1780 Gobara Hirooka, Shiojiri 399-0781, Japan.ORCID 0009-0002-9786-2581
Keisuke NakanoDepartment of Oral Pathology and Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama-city, Okayama 700-8558, Japan.ORCID 0000-0001-8316-8543

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma membrane transporters are increasingly recognized as potential drug targets for oral cancer, particularly oral squamous cell carcinoma (OSCC). These transporters play crucial roles in cancer cell metabolism, drug resistance, and the tumor microenvironment, making them attractive targets for therapeutic intervention. Among the two main families of plasma membrane transporters, ATP-binding cassette (ABC) transporters have long been known to be involved in drug efflux and contribute to chemoresistance in cancer cells. On the other hand, solute carriers (SLCs) are also a family of transporters that facilitate the transport of various substrates, including nutrients and drugs, and have recently been shown to contribute to cancer chemosensitivity, metabolism, and proliferation. SLC transporters have been identified as potential cancer biomarkers and therapeutic targets, and their expression profiles suggest that they could be utilized in precision oncology approaches. We summarize previous reports on the expression and role of ABC and SLC transporters in oral cancer and discuss their potential as therapeutic targets.

Indexed as

Antineoplastic AgentsCarcinoma, Squamous CellMembrane Transport ProteinsMouth NeoplasmsAnimalsATP-Binding Cassette TransportersBiomarkers, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapySolute Carrier ProteinsAntineoplastic AgentsATP-Binding Cassette TransportersBiomarkers, TumorMembrane Transport ProteinsSolute Carrier ProteinsABC transporteroral canceroral squamous cell carcinomaSLC transporter

Identifiers

PMID40362545
PMCPMC12072478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.